Mon, Sep 1, 2014, 5:06 PM EDT - U.S. Markets closed for Labor Day

Recent

% | $
Quotes you view appear here for quick access.

Allergan Inc. Message Board

  • cenmore2000 cenmore2000 Mar 21, 2000 1:50 PM Flag

    MUST READ:

    This trades for $3.25 a share on Cdnx Exchange.
    Do your research $$$$$$$
    Symbol =
    isa-x

    Isotechnika Inc. Announces the IND Filing of its New
    Immunosuppressive Drug ISAtx247 Application to The Food and Drug
    Administration (FDA) of the United States of America
    12:12
    EST Tuesday, March 21, 2000
    EDMONTON, March 21
    /CNW/ - Dr. Randall Yatscoff, President of Isotechnika
    Inc. is pleased to announce the IND filing of
    Isotechnika's new immunosuppressive drug ISAtx247 to The Food
    and Drug Administration to obtain approval to
    commence human clinical trials in the United States. A
    parallel filing with the Canadian Health Protection Branch
    received approval earlier this month.
    "This represents
    a significant milestone achievement for Isotechnika
    as it is the first drug in our pipeline to complete
    pre-clinical testing prior to entering human clinical trials.
    Parallel Phase 1 trials in humans will be performed in
    Canada and the United States. The Canadian trials will
    commence at the end of April. With the filing in the
    United States it is anticipated that trials will
    commence in that country later this spring. The completion
    of pre-clinical trials and the filing of the drug
    for approval for human trials in two countries in a
    short period of time speaks to the hard work,
    dedication and diligence of our core group of highly trained
    scientists" said Dr. Randall Yatscoff.
    ISAtx247 is a
    novel immunosuppressive drug, which is designed to be
    used for prevention of organ rejection after
    transplantation and for treatment of autoimmune diseases such as
    arthritis and psoriasis to name a few. Based on the
    completed pre-clinical studies, ISAtx247 demonstrates
    superior efficacy and reduced toxicity when compared with
    presently used medications such as Cyclosporine for
    prevention of organ rejection after transplantation and for
    treatment of autoimmune diseases. Current annual worldwide
    sales of Cyclosporine are in excess of $2 billion USD.
    "Subsequent to the completion of Phase 1 trials it is our
    intention to develop the drug for a number of transplant
    and autoimmune indications.

 
AGN
163.68+1.57(+0.97%)Aug 29 4:01 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Yahoo! Inc.
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT
Avago Technologies Limited
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT